Taysha Gene Therapies, Inc.
TSHA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $8 | $15 | $3 | $0 |
| % Growth | -46.1% | 517.5% | – | – |
| Cost of Goods Sold | $0 | $0 | $2 | $0 |
| Gross Profit | $8 | $15 | $0 | $0 |
| % Margin | 100% | 100% | 0.6% | – |
| R&D Expenses | $66 | $57 | $91 | $132 |
| G&A Expenses | $29 | $30 | $0 | $41 |
| SG&A Expenses | $29 | $30 | $35 | $41 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $5 | $1 | $0 | $0 |
| Operating Expenses | $100 | $88 | $126 | $173 |
| Operating Income | -$91 | -$72 | -$126 | -$173 |
| % Margin | -1,097.6% | -468.8% | -5,037.1% | – |
| Other Income/Exp. Net | $2 | -$39 | -$40 | -$1 |
| Pre-Tax Income | -$89 | -$112 | -$166 | -$175 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$89 | -$112 | -$166 | -$175 |
| % Margin | -1,071.6% | -722.1% | -6,635.3% | – |
| EPS | -0.357 | -0.961 | -3.777 | -4.635 |
| % Growth | 62.8% | 74.6% | 18.5% | – |
| EPS Diluted | -0.357 | -0.961 | -3.777 | -4.635 |
| Weighted Avg Shares Out | 250 | 116 | 44 | 38 |
| Weighted Avg Shares Out Dil | 250 | 116 | 44 | 38 |
| Supplemental Information | – | – | – | – |
| Interest Income | $7 | $4 | $0 | $0 |
| Interest Expense | $0 | $5 | $4 | $1 |
| Depreciation & Amortization | $1 | $1 | $2 | $0 |
| EBITDA | -$88 | -$105 | -$160 | -$173 |
| % Margin | -1,055.5% | -680.8% | -6,384.1% | – |